I-Mab (IMAB) IPO Opens Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
I-MAB Announces Pricing of U.S. Initial Public Offering
January 17, 2020 12:37 AM EST- ADSs to Begin Trading on Nasdaq on January 17, 2020 -
SHANGHAI, China and ROCKVILLE, Md., Jan. 17, 2020 (GLOBE NEWSWIRE) -- I-Mab (I-Mab or the Company) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced the pricing of its initial public offering of 7,407,400 American Depositary Shares (ADSs), each ten (10) ADSs representing twenty-three (23) ordinary shares of the Company, par value US$0.0001 per share, at US$14.00 per ADS, assuming the... More
